Detailed price information for Coherus Oncology Inc (CHRS-Q) from The Globe and Mail including charting and trades.

Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.

Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 ...

As of Friday, January 09, Coherus Oncology, Inc.’s CHRS share price has surged by 6.86%, which has investors questioning if ...

As someone who's followed the evolution of cancer treatments closely—both personally, having supported loved ones through their battles, and professionally in the pharmaceutical space—I've been ...

-Data show CCR8 target is present with high prevalence and density in many solid tumors- ...

Investing.com -- Coherus BioSciences Inc (NASDAQ:CHRS) stock rose 5.8% on Monday following the publication of research supporting the potential of its investigational cancer treatment tagmokitug.

Chinese patients with advanced acral melanoma achieved a small but significant increase in progression-free survival when treated with toripalimab versus dacarbazine. While the overall response rate ...

SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...

A recent study found that monthly prices of checkpoint inhibitors decreased only slightly from 2015 to 2024, with declines in annual average sales prices ranging from 0.21% to 4.85%. Checkpoint ...

Disitamab vedotin/toripalimab improved PFS and OS vs chemotherapy in HER2-expressing advanced urothelial carcinoma, per phase 3 RC48-C016 data. Frontline treatment with disitamab vedotin plus ...